Pretreated EGFRdel19/ BRAFV600E Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report

Corrado Orciuolo; Federico Cappuzzo; Lorenza Landi; Blerina Resuli; Silvia Carpano; Antonello Vidiri; Simonetta Buglioni; Chiara Mandoj; Gennaro Ciliberto; Gabriele Minuti

doi:10.1016/j.jtocrr.2023.100545

Pretreated EGFR^del19/ BRAF^V600E Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report

JTO Clin Res Rep. 2023 Jun 30;4(8):100545. doi: 10.1016/j.jtocrr.2023.100545. eCollection 2023 Aug.

Affiliations

¹ Division of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy.
² Clinical Trials Center: Phase 1 and Precision Medicine, IRCCS National Cancer Institute Regina Elena, Rome, Italy.
³ IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Abstract

Oncogene-addicted NSCLC inevitably becomes resistant to targeted therapy by developing acquired resistance through on- or off-target mechanisms, potentially detectable by liquid biopsy. We present the first reported case of a patient with pretreated EGFR^del19/BRAF^V600E lung adenocarcinoma and symptomatic leptomeningeal metastasis obtaining durable clinical benefit on osimertinib, dabrafenib, and trametinib treatment.

Keywords: Case report; NSCLC; Osimertinib; Resistance; Targeted therapy.

Publication types

Case Reports